Contineum Therapeutics, Inc. (CTNM) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Contineum Therapeutics, Inc. (CTNM) closed at USD 8.14 on 2026-10-14, a change of -26.2 % over the past year, with a market capitalization of USD 297.21M.

Contineum Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Contineum Therapeutics, Inc. key figures

Previous close

USD 8.14 (2026-10-14)

1-year change

-26.2 %

Market cap

USD 297.21M

Enterprise value

USD 67.23M

P/E ratio (trailing)

-4.88

P/E ratio (forward)

-4.10

EPS (trailing)

-1.62

EPS (forward)

-1.93

PEG ratio

n/a

Price to book

1.24

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.03

Employees

51

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Contineum Therapeutics, Inc.

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Contineum Therapeutics, Inc. and compare it with other stocks.